JOHN C REED
CIK 1181561 · EVP, Innovative Medicine, R&D · last filed 2026-08-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$348.5K
Companies
6
Total Filings
34
Lifetime Open-Market Net
-$20.82M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MDGL | Director | 647 | $538.71 | $348.5K | $0 | 1 | 2026-08-18 |
| JOHNSON & JOHNSON (JNJ.WD) Delisted | EVP, Innovative Medicine, R&D | 24,911 | — | — | -$20.42M | 10 | 2026-05-04 |
| JNJ | EVP, Pharmaceuticals R&D | — | $271.19 | — | $0 | 1 | 2023-05-02 |
| IONIS PHARMACEUTICALS INC (ISIS) Delisted | Director | 0 | — | — | -$402.2K | 9 | 2012-09-06 |
| Clovis Oncology, Inc. (CLVS) Delisted | Director | — | $0.08 | — | $0 | 1 | 2012-06-15 |
| PHARMION CORP (PHRM) Delisted | Director | — | — | — | $0 | 1 | 2007-06-07 |
Recent Filings · Page 2 of 4
34 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-18 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Mixed | +965 | -$60.1K | EDGAR |
| 2024-10-31 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Mixed | +14,271 | -$1.59M | EDGAR |
| 2024-05-03 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Mixed | +11,271 | -$1.59M | EDGAR |
| 2024-02-20 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-02 | JNJ | Grant (A) | — | $0 | EDGAR |
| 2012-09-06 | IONIS PHARMACEUTICALS INC (ISIS) Delisted | Mixed | — | -$100.0K | EDGAR |
| 2012-07-11 | IONIS PHARMACEUTICALS INC (ISIS) Delisted | Mixed | — | -$100.4K | EDGAR |
| 2012-07-03 | IONIS PHARMACEUTICALS INC (ISIS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-22 | IONIS PHARMACEUTICALS INC (ISIS) Delisted | Mixed | — | -$29.1K | EDGAR |
| 2012-06-15 | Clovis Oncology, Inc. (CLVS) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.